[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.136.184. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
January 2019

Hypofractionated Nodal Irradiation for Breast Cancer: A Case for Caution

Author Affiliations
  • 1Department of Radiation Oncology, University Hospital of Martinique, Bld Pasteur, Fort-de-France, Martinique
  • 2Department of Radiation Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Laarbeeklaan, Brussels, Belgium
  • 3Department of Radiation Oncology, Howard University Hospital, Washington, DC
  • 4Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
JAMA Oncol. 2019;5(1):13-14. doi:10.1001/jamaoncol.2018.5061

Hypofractionation for breast cancer radiotherapy is attracting considerable attention.1 Compared with conventional therapy, hypofractionation delivers a full course of treatment in fewer sessions, which may improve patient convenience and reduce treatment costs. There is a growing trend to extend the therapy’s indication to regional nodal irradiation (RNI). The question is whether this is wise. We assessed meta-analyses of breast cancer radiotherapy and have found cause for caution in extending the use of hypofractionation to RNI until data from prospective clinical trials become available. Data needed to improve decision making for extending hypofractionation use may include short- and long-term data on the repercussions of this therapy for lung and heart function and noncancer morbidity/mortality.

×